Tumour Infiltrating Lymphocyte Therapy Hubs for Melanoma

Access full document

Details

Contract Title:Tumour Infiltrating Lymphocyte Therapy Hubs for Melanoma
Published Date:May 20, 2025
Notice Type:Notice (CompetitiveContractNotice)
Value Banding:Low Value
Delivery Point:United Kingdom

Description:

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential of many unwarranted side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to ITU....


Back to search results